Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 14,097 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Control Clear all
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers

NCT00545298
View directory record Official record
Conditions
Venous Ulcers
Interventions
Nitric Oxide - same dose 6 wks, Nitric Oxide modified treatment
Drug
Lead sponsor
Nitric BioTherapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Oct 25, 2026, 8:47 PM EDT
Terminated Not applicable Interventional

AcoArt Litos PCB Below-the-knee Global Trial

NCT06330493
View directory record Official record
Conditions
Chronic Limb-Threatening Ischemia
Interventions
PCB, PTA
Device
Lead sponsor
Acotec Scientific Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
16
States / cities
Concord, California • Fremont, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 2 Interventional Results available

Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT04906421
View directory record Official record
Conditions
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Interventions
TVB-2640, Placebo
Drug · Other
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
103
States / cities
Huntsville, Alabama • Madison, Alabama • Sun City, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 25, 2026, 8:47 PM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy

NCT04412252
View directory record Official record
Conditions
COVID-19
Interventions
Tofacitinib, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
6
States / cities
Hartford, Connecticut • Iowa City, Iowa • Shreveport, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 25, 2026, 8:47 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs

NCT00683436
View directory record Official record
Conditions
Primary Insomnia
Interventions
Adipiplon, Placebo, Ambien CR
Drug
Lead sponsor
Neurogen Corporation
Industry
Eligibility
21 Years to 64 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Pembroke Pines, Florida • South Miami, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2008 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

NCT05611671
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Colitis, Ulcerative
Interventions
MORF-057, Placebo
Drug
Lead sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Industry
Eligibility
18 Years to 85 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Sun City, Arizona • Lancaster, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 TP-271 Oral PK Single Ascending Dose Study

NCT03024034
View directory record Official record
Conditions
Bacterial Infections
Interventions
TP-271
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 3 Interventional Results available

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)

NCT03449134
View directory record Official record
Conditions
Chronic Cough
Interventions
Placebo, Gefapixant
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Litchfield Park, Arizona • Scottsdale, Arizona • La Mesa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users

NCT02218021
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Samidorphan, Placebo, Oxycodone
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 25, 2026, 8:47 PM EDT
Terminated Phase 2 Interventional Results available

Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03616821
View directory record Official record
Conditions
Ulcerative Colitis, IBD
Interventions
Brazikumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 3 Interventional Results available

Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis

NCT03928184
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Lorecivivint, Placebo
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
99
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Translation Study of a Safe Teen Driving Intervention

NCT04317547
View directory record Official record
Conditions
Drive, Adolescent Behavior, Risk Behavior
Interventions
Steering Teens Safe (STS), Driving Feedback Technology.
Behavioral
Lead sponsor
Ginger Yang
Other
Eligibility
16 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 2 Interventional Results available

Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)

NCT02128958
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
CF102, Placebo
Drug
Lead sponsor
Can-Fite BioPharma
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Aurora, Colorado • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B

NCT01386528
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia B
Interventions
nonacog beta pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
13 Years to 70 Years · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 2 Interventional

Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

NCT03339128
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
26
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Corona, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125

NCT02673567
View directory record Official record
Conditions
Pharmacokinetics
Interventions
TEV-48125 - 1, TEV-48125 - 2, TEV-48125 - 3, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease

NCT06343636
View directory record Official record
Conditions
Healthy, Alzheimer Disease
Interventions
VG-3927, Placebo
Drug
Lead sponsor
Vigil Neuroscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Maitland, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury

NCT01143064
View directory record Official record
Conditions
Brain Injuries
Interventions
Progesterone, Lipid emulsion without progesterone
Drug
Lead sponsor
BHR Pharma, LLC
Industry
Eligibility
16 Years to 70 Years
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
53
States / cities
Mobile, Alabama • Los Angeles, California • San Diego, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions

NCT02277704
View directory record Official record
Conditions
PTSD
Interventions
TNX-102 SL, Placebo
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Imperial, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 25, 2026, 8:47 PM EDT
Terminated Early Phase 1 Interventional

HCL Single Arm Pilot Study in Treatment of Hyperglycemia of Pediatric ALL

NCT05006040
View directory record Official record
Conditions
High Risk Acute Lymphoblastic Leukemia
Interventions
Hybrid Closed Loop System
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 26 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 2 Interventional Results available

A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma

NCT00207740
View directory record Official record
Conditions
Asthma
Interventions
CNTO148, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
29
States / cities
Los Angeles, California • San Diego, California • Stockton, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

NCT02207790
View directory record Official record
Conditions
Healthy Subjects
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years to 60 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Phase 3 Interventional Results available

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

NCT05850520
View directory record Official record
Conditions
Macular Edema Secondary to Retinal Vein Occlusion
Interventions
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
Drug · Diagnostic Test
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Fullerton, California • Long Beach, California • Mountain View, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 25, 2026, 8:47 PM EDT
Completed Not applicable Interventional

Partnered Rhythmic Rehabilitation in Prodromal Alzheimer's Disease

NCT04029623
View directory record Official record
Conditions
Prodromal Alzheimer's Disease
Interventions
Partnered Rhythmic Rehabilitation (PRR), Group walking (WALK)
Other
Lead sponsor
Emory University
Other
Eligibility
50 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 25, 2026, 8:47 PM EDT